ABOUT THIS FUND
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
PRICE
$19.16 ▲ UP 48.35% (+$73.38)—
No price history available for GERM over this range.
HOLDINGS
TOP 20 OF 46 · 76.34% OF THE FUNDRANK STOCK WEIGHT SHARES VALUE
